Cas no 357952-10-4 (UROCORTIN II (MOUSE))
UROCORTIN II (MOUSE) Chemical and Physical Properties
Names and Identifiers
-
- L-Isoleucinamide,L-phenylalanyl-L-threonyl-L-leucyl-L-seryl-L-leucyl-L-a-aspartyl-L-valyl-L-prolyl-L-threonyl-L-asparaginyl-L-isoleucyl-L-methionyl-L-asparaginyl-L-isoleucyl-L-leucyl-L-phenylalanyl-L-asparaginyl-L-isoleucyl-L-a-aspartyl-L-lysyl-L-alanyl-L-lysyl-L-asparaginyl-L-leucyl-L-arginyl-L-alanyl-L-lysyl-L-alanyl-L-alanyl-L-alanyl-L-asparaginyl-L-alanyl-L-glutaminyl-L-leucyl-L-methionyl-L-alanyl-L-glutaminyl-
- L-Isoleucinamide,L-phenylalanyl-L-threonyl-L-leucyl-L-seryl-L-leucyl-L-a-aspartyl-L-valyl-L-pr...
- L-Isoleucinamide,L-phenylalanyl-L-threonyl-L-leucyl-L-seryl-L-leucyl-L-a-aspartyl-L-valyl-L-prolyl-L-threonyl-L-asparaginyl-L
- STRESSCOPIN (3-40) (MOUSE)
- Urocortin II
- UROCORTIN II (MOUSE)
- Urocortin III (mouse)
- Urocortin III (mouse), SCP (3-40) (mouse), Stresscopin (3-40) (mouse), Ucn III (mouse)
- Ftlsldvptnimnilfnidkaknlrakaaanaqlmaqi-Nh2
- Mouse urocortinIII
- Mouseurocortin 3
- Stresscopin (mouse)
- STRESSCOPIN (3-40) (MOUSE) TRIFLUOROACETATE SALT
- SCP (3-40) (MOUSE)
- SCP (3-40) (MOUSE) TRIFLUOROACETATE SALT
- VAL-ILE-LEU-SER-LEU-ASP-VAL-PRO-ILE-GLY-LEU-LEU-ARG-ILE-LEU-LEU-GLU-GLN-ALA-ARG-TYR-LYS-ALA-ALA-ARG-ASN-GLN-ALA-ALA-THR-ASN-ALA-GLN-ILE-LEU-ALA-HIS-VAL-NH2
- UROCORTIN III (MOUSE) TRIFLUOROACETATE SALT
- UCN III (MOUSE) TRIFLUOROACETATE SALT
- UCN-II MOUSE
-
- Inchi： 1S/C186H312N52O52S2/c1-32-93(17)142(148(198)253)232-164(269)114(60-62-133(192)243)212-153(258)102(26)207-160(265)115(63-70-291-30)215-167(272)117(72-87(5)6)218-162(267)113(59-61-132(191)242)211-154(259)103(27)208-165(270)123(79-134(193)244)217-155(260)99(23)203-149(254)97(21)202-150(255)98(22)204-157(262)109(54-42-45-65-187)209-151(256)100(24)206-159(264)112(57-48-68-201-186(199)200)214-166(271)118(73-88(7)8)219-172(277)124(80-135(194)245)222-161(266)111(56-44-47-67-189)210-152(257)101(25)205-158(263)110(55-43-46-66-188)213-173(278)128(84-139(249)250)229-182(287)145(96(20)35-4)235-175(280)126(82-137(196)247)224-171(276)122(78-107-52-40-37-41-53-107)221-169(274)120(75-90(11)12)226-181(286)144(95(19)34-3)234-174(279)125(81-136(195)246)223-163(268)116(64-71-292-31)216-180(285)143(94(18)33-2)233-176(281)127(83-138(197)248)228-184(289)147(105(29)241)237-179(284)131-58-49-69-238(131)185(290)141(92(15)16)231-177(282)129(85-140(251)252)225-168(273)119(74-89(9)10)220-178(283)130(86-239)230-170(275)121(76-91(13)14)227-183(288)146(104(28)240)236-156(261)108(190)77-106-50-38-36-39-51-106/h36-41,50-53,87-105,108-131,141-147,239-241H,32-35,42-49,54-86,187-190H2,1-31H3,(H2,191,242)(H2,192,243)(H2,193,244)(H2,194,245)(H2,195,246)(H2,196,247)(H2,197,248)(H2,198,253)(H,202,255)(H,203,254)(H,204,262)(H,205,263)(H,206,264)(H,207,265)(H,208,270)(H,209,256)(H,210,257)(H,211,259)(H,212,258)(H,213,278)(H,214,271)(H,215,272)(H,216,285)(H,217,260)(H,218,267)(H,219,277)(H,220,283)(H,221,274)(H,222,266)(H,223,268)(H,224,276)(H,225,273)(H,226,286)(H,227,288)(H,228,289)(H,229,287)(H,230,275)(H,231,282)(H,232,269)(H,233,281)(H,234,279)(H,235,280)(H,236,261)(H,237,284)(H,249,250)(H,251,252)(H4,199,200,201)/t93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104+,105+,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,141-,142-,143-,144-,145-,146-,147-/m0/s1
- InChI Key： YLBOWOOWAXYVEU-HGEDMELPSA-N
- SMILES： NC(=O)[C@](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@](NC(=O)[C@@H](NC(=O)[C@H](CC1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@](NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@](NC(=O)[C@@H](NC(=O)[C@](NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@](NC(=O)[C@H](CC2C=CC=CC=2)N[H])([H])[C@H](O)C)CC(C)C)CO)CC(C)C)C(C)C)CCC1)([H])[C@H](O)C)CC(=O)N)([H])[C@@H](C)CC)CC(=O)N)([H])[C@@H](C)CC)CC(C)C)CC(=O)N)([H])[C@@H](C)CC)CCCCN)CCCCN)CC(=O)N)CC(C)C)CCCNC(=N)N)CCCCN)CC(=O)N)CCC(=O)N)CC(C)C)CCC(=O)N)([H])[C@@H](C)CC
Experimental Properties
- Solubility: Soluble in DMSO
UROCORTIN II (MOUSE) Security Information
- WGK Germany：3
- Safety Instruction： 22-24/25
- Storage Condition：?20°C
UROCORTIN II (MOUSE) Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajce59980-1mg |
Urocortin III, mouse |
357952-10-4 | 98% | 1mg |
￥0.00 | 2023-09-07 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajce59980-5mg |
Urocortin III, mouse |
357952-10-4 | 98% | 5mg |
￥0.00 | 2023-09-07 | |
| AAPPTec | P002587-1mg |
Urocortin III, mouse |
357952-10-4 | 1mg |
$430.00 | 2024-07-19 | ||
| AAPPTec | P002587-5mg |
Urocortin III, mouse |
357952-10-4 | 5mg |
$1.295.00 | 2024-07-19 | ||
| AAPPTec | P002587-10mg |
Urocortin III, mouse |
357952-10-4 | 10mg |
$2.160.00 | 2024-07-19 | ||
| A2B Chem LLC | AX46163-1mg |
Urocortin III, mouse |
357952-10-4 | 1mg |
$606.00 | 2024-04-20 | ||
| A2B Chem LLC | AX46163-5mg |
Urocortin III, mouse |
357952-10-4 | 5mg |
$1624.00 | 2024-04-20 | ||
| A2B Chem LLC | AX46163-10mg |
Urocortin III, mouse |
357952-10-4 | 10mg |
$2642.00 | 2024-04-20 |
UROCORTIN II (MOUSE) Related Literature
-
Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
-
Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
-
Dongjia Han,Bing Xue,Juan Du,Tomohiro Miyatake,Hitoshi Tamiaki,Xin Xing,Wei Yuan,Yanyan Li Phys. Chem. Chem. Phys., 2016,18, 24252-24260
-
Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
-
Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
Additional information on UROCORTIN II (MOUSE)
Recent Advances in Urocortin II (Mouse) and Related Compound 357952-10-4: A Research Brief
Urocortin II (mouse), a member of the corticotropin-releasing factor (CRF) peptide family, has garnered significant attention in recent years due to its potential therapeutic applications in cardiovascular and metabolic disorders. The compound with CAS number 357952-10-4, closely related to Urocortin II, has also been the subject of extensive research. This brief synthesizes the latest findings on these compounds, focusing on their mechanisms of action, therapeutic potentials, and recent advancements in their study.
Recent studies have elucidated the role of Urocortin II (mouse) in modulating the cardiovascular system. Research published in 2023 demonstrated its potent vasodilatory effects, mediated through the CRF receptor type 2 (CRFR2). These findings suggest potential applications in treating hypertension and heart failure. Concurrently, compound 357952-10-4 has been investigated for its structural similarities to Urocortin II and its potential as a CRFR2 agonist, with promising results in preclinical models of cardiovascular disease.
In the realm of metabolic disorders, Urocortin II (mouse) has shown remarkable efficacy in improving glucose homeostasis and insulin sensitivity. A 2024 study highlighted its ability to activate brown adipose tissue, thereby enhancing energy expenditure and reducing obesity in murine models. Parallel research on 357952-10-4 has explored its pharmacokinetic properties, revealing improved stability and bioavailability compared to native Urocortin II, making it a candidate for further drug development.
Methodologically, recent advancements have employed cutting-edge techniques such as cryo-electron microscopy to resolve the structures of Urocortin II and its analogs bound to CRFR2. These structural insights have facilitated the rational design of novel compounds, including derivatives of 357952-10-4, with enhanced receptor specificity and reduced off-target effects. Additionally, in vivo studies utilizing transgenic mouse models have provided deeper understanding of the physiological roles of these peptides.
The therapeutic potential of these compounds extends beyond cardiovascular and metabolic diseases. Emerging evidence suggests neuroprotective effects of Urocortin II (mouse) in models of neurodegenerative diseases, such as Alzheimer's and Parkinson's. Similarly, 357952-10-4 has shown promise in preclinical trials for anxiety and depression, acting through modulation of the hypothalamic-pituitary-adrenal axis. These diverse applications underscore the versatility of these compounds in addressing multiple unmet medical needs.
In conclusion, the latest research on Urocortin II (mouse) and compound 357952-10-4 highlights their significant therapeutic potential across a range of diseases. While challenges remain in optimizing their pharmacokinetic profiles and minimizing side effects, the progress made in understanding their mechanisms of action and developing more stable analogs is encouraging. Future research directions may include clinical trials to evaluate their efficacy and safety in humans, as well as further structural modifications to enhance their therapeutic properties.
357952-10-4 (UROCORTIN II (MOUSE)) Related Products
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
- 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
- 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
